Dupilumab‐associated hypereosinophilia in patients treated for moderate‐to‐severe atopic dermatitis

Abstract

Trials assessing dupilumab in atopic dermatitis (AD) showed transient eosinophilia in less than 2% of patients (1). The frequency of hypereosinophilia (HE), defined as eosinophil blood count (EBC) ≥1500/mm3 (2), was higher (15.8%) in our previous real-life cohort of AD patients treated with dupilumab (3). Since symptomatic HE was reported in asthma trials, we aimed to assess the clinical impact of HE in AD patients receiving dupilumab.